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patients previously infected with another sero-
type. Preexisting nonneutralizing heterotypic 
antibodies bind to DENV and facilitate infection 
of monocytes, which triggers an inflammatory 
cascade that is eventually responsible for en-
hanced disease severity.1 Recently, Katzelnick 
et al. found that patients with anti-DENV titers 
of 1:21 to 1:80 were at the highest risk for severe 
dengue.2 The importance of antibody concentra-
tion is particularly relevant, because postvaccina-
tion anti-DENV titers wane with time in patients 
without natural reexposure.3,4
Consequently, children who were seronegative 
before vaccination and whose postvaccination 
antibody titers wane are most at risk for severe 
disease. Studies should therefore evaluate wheth-
er booster doses could protect these patients from 
subsequent severe disease.
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H4:IC31 Vaccine or BCG Revaccination for Tuberculosis
To the Editor: Nemes and colleagues (July 12 
issue)1 examined the effects of bacille Calmette–
Guérin (BCG) revaccination on reducing the rate 
of sustained QuantiFERON-TB Gold In-tube assay 
(QFT) conversion among adolescents in a high-
risk setting. One aspect that received relatively 
little attention in the trial regards the immuno-
logic mechanisms responsible for these effects, 
which were assessed only by measurement of 
interferon-γ and interleukin-2 T-cell responses. 
Studies have shown a combination of improved 
long-term innate or trained immunity (through 
epigenetic reprogramming of myeloid cells) and 
adaptive responses after BCG vaccination, which 
leads to more effective control of mycobacterial 
and unrelated infections.2-4 These mechanisms can 
also explain the decrease in unrelated respiratory 
tract infections after BCG revaccination that was 
observed by the authors. This decrease is consis-
tent with the nonspecific beneficial effects after 
BCG vaccination that have been observed repeat-
edly in persons included in epidemiologic stud-
ies,5 especially in infants, and warrants sustained 
attention in future investigations.
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